"I don't think it is correct to assume that testing will only be for/against vascular dementia."

I agree Tada. The BETonMACE cognition sub-study to investigate apabetalone effect on change in MoCA score isn't necessarily specific to vascular cognitive dementia or Alzheimer's. There is no cognition trial design finalized yet for the follow up trial. There is no follow up cognition trial listed on ClinicalTrials.gov. As Tada noted, the team will be looking very closely at the full BETonMACE data set to gain insight and inform future cognition trial(s). With all of the banked blood samples, they may even do some further testing to gain a better understanding. The aducanumab Alzheimer's trial flop presents an opportunity. However, it would be foolish to jump onto the Alzheimer's bandwagon without solid scientific/clinical basis. I trust the neurodegenerative disease clinical steering group together with Resverlogix scientists to make this kind of decision. If CVD disease presents a big risk for vascular cognitive dementia (VCD), and BETonMACE is more enriched with VCD patients than Alzheimer's patients, and the BETonMACE cognition sub-study yield promising results, then it is a no brainer to pursue a VCD focused trial. However, that does not mean that a separate Alzheimer's focused trial won't happen in the future too. 

BearDownAZ